CDK1 is up-regulated by temozolomide in an NF-κB dependent manner in glioblastoma

CDK1 is up-regulated by temozolomide in an NF-κB dependent manner in glioblastoma

Abstract The alkylating agent, temozolomide (TMZ), is the most commonly used chemotherapeutic for the treatment of glioblastoma (GBM). The anti-glioma effect of TMZ involves a complex response that includes G2-M cell cycle arrest and cyclin-dependent kinase 1 (CDK1) activation. While CDK1 phosphoryl...

Full description

Bibliographic Details
Main Authors: David J. Voce, Giovanna M. Bernal, Kirk E. Cahill, Longtao Wu, Nassir Mansour, Clayton D. Crawley, Paige-Ashley S. Campbell, Ainhoa Arina, Ralph R. Weichselbaum, Bakhtiar Yamini
Format: Article
Language:English
Published: Nature Publishing Group 2021-03-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-84912-4

Internet

https://doi.org/10.1038/s41598-021-84912-4

Similar Items